和铂医药-B(02142.HK):HBM7004用于治疗晚期实体瘤的新药临床试验申请获国家药监局批准

智通财经
Aug 18
【和铂医药-B(02142.HK):HBM7004用于治疗晚期实体瘤的新药临床试验申请获国家药监局批准】智通财经APP讯,和铂医药-B(02142.HK)公布,HBM7004(一款治疗晚期实体瘤的新型 B7H4xCD3双特异性抗体)的新药临床试验(IND)申请已获中国国家药品监督管理局批准。此乃继集团获美国食品药品监督管理局(FDA)许可其IND申请于美国启动首次人体I期临床试验后取得的又一进展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10